A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of a Probe CYP3A4 Inhibitor and Inducer on the Pharmacokinetics of BAY1841788 (ODM 201) in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Darolutamide (Primary) ; Itraconazole; Rifampicin
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Bayer
- 28 Jul 2017 Status changed from active, no longer recruiting to completed.
- 04 May 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2017 Planned End Date changed from 1 Jul 2017 to 5 Jul 2017.